Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAPIX-ALL: Apixaban for VTE Prevention in Pediatric ALL/Lymphoma
NCT02369653Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2015
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of apixaban in venous thromboembolism (VTE), sponsored by Bristol Myers Squibb. Started Oct 2015; status: completed.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02369653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02369653.